TLV •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization20.64 mln
Float601 mln
Earnings Date08/20/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
49
/ 100
In line with market
Debt / Equity
-1.84
Negative equity
ROE
-248
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 1993 and based in Ramat Gan, Israel, XTL Biopharmaceuticals focuses on finding and advancing treatments for autoimmune conditions. Its most advanced product, hCDR1, is prepared to enter Phase II clinical trials and targets diseases such as lupus and Sjogren's syndrome. The company holds a licensing agreement with Yeda Research and Development to support the ongoing study and future commercialization of hCDR1.
